Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > TOP STORIES
TOP STORIES
-
ACADEMIA Alzheimer’s-Related Guidelines Being Revised to Accommodate Kisunla, Rexulti
November 6, 2024
-
ACADEMIA Japan Crafting Registry of All Hemophilia Patients, Company Use Eyed Too
November 5, 2024
-
REGULATORY Advisory Panel Backs Transfer of GMP Inspection Authority for New Generics to PMDA
November 5, 2024
-
REGULATORY PMDA Opens US Office in Washington, D.C.
November 5, 2024
-
BUSINESS FDA Rolling Submission for Leqembi SC Completed: Eisai
November 5, 2024
-
BUSINESS Kyowa Kirin Picks Abdul Mullick as New President and COO
November 1, 2024
-
BUSINESS Otsuka Holdings Names Makoto Inoue as New CEO
November 1, 2024
-
REGULATORY BeiGene’s Brukinsa, J&J’s Balversa and More Now in Line for Japan Approval
October 31, 2024
-
BUSINESS 604 Employees Raise Hands for Sumitomo’s Buyout Program
October 31, 2024
-
ACADEMIA 50% of Quit-Smoking Clinics Closed or Suspended, Will Champix Re-Supply Bring Them Back Online?
October 30, 2024
-
REGULATORY Ruling Bloc’s Loss of Lower House Majority Might Sway Off-Year Revision Debates
October 29, 2024
-
REGULATORY LDP Loses Big in Snap Election, Many Health-Savvy Members Ousted
October 28, 2024
-
BUSINESS AbbVie Taps Tiago Campos Rodrigues as Japan President
October 28, 2024
-
BUSINESS Recordati to Enter Japan’s Hematology/Oncology Market with Enjaymo Acquisition
October 25, 2024
-
BUSINESS NHI-Market Price Gap Expected to Contract in 2024, Will It Enter Lower 5% Territory?
October 24, 2024
-
BUSINESS CEA Is “Wrong Tool” That Doesn’t Fit into Japanese System: J&J Exec
October 23, 2024
-
REGULATORY LDP’s Hashimoto Makes Rare Speech on Drug Prices amid Close Race in Okayama
October 22, 2024
-
BUSINESS Pfizer Veteran Pullicino to Lead Novartis Japan
October 22, 2024
-
BUSINESS Ferring Japan Set for 15% Annual Growth as It Gazes at Gene Therapy Debut
October 21, 2024
-
BUSINESS Moderna CEO Maintains Future Vision for Product Mix despite R&D Cutback, Eyes Leap with Flu-COVID Shot
October 18, 2024
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…